Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

CyrusOne Reports First Quarter 2019 Earnings

Published

on

Reading Time: 13 minutes

1Q’19 Year-over-Year Revenue Growth of 14%
Signed $27
Million in Annualized GAAP Revenue and 16 Megawatts

DALLAS–(BUSINESS WIRE)–CyrusOne Inc. (NASDAQ: CONE), a premier global data center REIT, today
announced first quarter 2019 earnings.

Highlights

           
% Change vs. 1Q’18

Category

1Q’19

1Q’18

     

1Q’18 Adjusted
for ASC 8421

Revenue $225.0 million 14% 14%
Net income / (loss) $89.4 million n/m n/m
Adjusted EBITDA $119.2 million 9% 13%
Normalized FFO $89.3 million 9% 12%
Net income / (loss) per diluted share $0.82 82% 86%
Normalized FFO per diluted share $0.82 (4)% (1)%
 

Leased 16 megawatts (“MW”) and 93,000 colocation square feet (“CSF”)
in the first quarter, totaling $27 million in annualized GAAP revenue
 

 

— Backlog of $39 million in annualized GAAP revenue as of the end
of the first quarter

 

As previously announced, acquired 22 acres of land in San Antonio
and 8 acres of land in Santa Clara to support growth in those markets
 
— Estimated 120 MW of power capacity in San Antonio and nearly 200
MW of power capacity in Santa Clara (inclusive of previously
acquired land)
 

Strategically hedged EUR exposure, synthetically converting $270
million outstanding on the Company’s revolving credit facility into
more attractively priced EUR-denominated debt (equivalent to €238
million), resulting in a nearly 300 basis point decrease in the
interest rate
 

Raised approximately $252 million in net proceeds through the sale
of approximately 4.9 million shares of common stock under
at-the-market (“ATM”) equity program
 

As previously announced, subsequent to the end of the first quarter
raised approximately $200 million through the sale of approximately
5.7 million American depository shares (“ADSs”) of GDS Holdings
Limited (“GDS”)
 

Increasing 2019 Normalized FFO per diluted share guidance2
by $0.20 at the midpoint of the range, from $3.10 – 3.20 to $3.30
– 3.40

 

“We are off to a great start to the year, with strong operational and
financial performance, and leasing contributions across the portfolio as
our international expansion creates an increasingly balanced and
diversified business with a presence in the most important markets in
the world,” said Gary Wojtaszek, president and chief executive officer
of CyrusOne. “We continue to maintain a very strong balance sheet to
support our growth, and recent initiatives have allowed us to
significantly increase our Normalized FFO per share guidance while
meeting our equity funding requirements for the year based on our
current outlook.”

First Quarter 2019 Financial Results

Revenue was $225.0 million for the first quarter, compared to $196.6
million for the same period in 2018, an increase of 14%. The increase in
revenue was driven primarily by a 22% increase in occupied CSF from
organic growth and the Zenium acquisition, as well as additional
interconnection services.

Net income was $89.4 million for the first quarter, compared to net
income of $43.5 million in the same period in 2018. Net income for the
first quarter included a $101.2 million unrealized gain on the Company’s
equity investment in GDS, a leading data center provider in China, due
to an increase in GDS’s share price during the quarter. Net income per
diluted common share3 was $0.82 in the first quarter of 2019,
compared to net income per diluted common share of $0.45 in the same
period in 2018.

Net operating income (“NOI”)4 was $141.7 million for the
first quarter, compared to $128.8 million in the same period in 2018, an
increase of 10%. Adjusted EBITDA5 was $119.2 million for the
first quarter, compared to $109.5 million in the same period in 2018, an
increase of 9%.

Normalized Funds From Operations (“Normalized FFO”)6 was
$89.3 million for the first quarter, compared to $82.2 million in the
same period in 2018, an increase of 9%. Normalized FFO per diluted
common share was $0.82 in the first quarter of 2019.

Leasing Activity

CyrusOne leased approximately 16 MW of power and 93,000 CSF in the first
quarter, representing $2.3 million in monthly recurring rent, inclusive
of the monthly impact of installation charges, or approximately $27.2
million in annualized GAAP revenue7, excluding estimates for
pass-through power. The weighted average lease term of the new leases,
based on square footage, is 56 months (4.7 years), and the weighted
average remaining lease term of CyrusOne’s portfolio is 56 months
(taking into account the impact of the backlog). Recurring rent churn8
for the first quarter was 2.1%, compared to 0.5% for the same period in
2018.

Portfolio Development and CSF Leased

In the first quarter, the Company completed construction on 249,000 CSF
and 48 MW of power capacity across five projects in Northern Virginia,
the New York Metro area, and Raleigh-Durham. CSF leased9 as
of the end of the first quarter was 90% for stabilized properties10
and 86% overall. In addition, the Company has development projects
underway in Northern Virginia, Dallas, the New York Metro area,
Raleigh-Durham, Phoenix, Austin, Frankfurt, London, and Amsterdam that
are expected to add approximately 190,000 CSF and 82 MW of power
capacity.

Sale of GDS Shares

As previously announced, subsequent to the end of the first quarter the
Company raised approximately $200 million through the sale of
approximately 5.7 million ADSs of GDS. CyrusOne continues to hold
approximately 2.3 million ADSs, valued at approximately $90 million
based on the GDS closing price on April 30, 2019, with the remaining
ADSs being subject to a six-month lock up period. The commercial
agreement between CyrusOne and GDS remains in place, and Gary Wojtaszek
remains a member of the GDS Board of Directors.

Balance Sheet and Liquidity

As of March 31, 2019, the Company had gross asset value11
totaling approximately $7.1 billion, an increase of approximately 32%
over gross asset value as of March 31, 2018. CyrusOne had $2.92 billion
of long-term debt12, $126.0 million of cash and cash
equivalents, and $1.28 billion available under its unsecured revolving
credit facility as of March 31, 2019. Net debt12 was $2.82
billion as of March 31, 2019, representing approximately 33% of the
Company’s total enterprise value as of March 31, 2019 of $8.6 billion.

In the first quarter, CyrusOne sold approximately 4.9 million shares of
its common stock through its ATM equity program, raising approximately
$252 million in net proceeds. The settlement of a portion of the shares
and receipt of the associated proceeds occurred in April 2019. As of
March 31, 2019, there was approximately $495 million in remaining
availability under the current ATM program. Also in the first quarter,
CyrusOne strategically hedged its EUR exposure, synthetically converting
$270 million outstanding on the Company’s revolving credit facility into
more attractively priced EUR-denominated debt (equivalent to €238
million), resulting in a nearly 300 basis point decrease in the interest
rate.

Subsequent to the end of the first quarter, CyrusOne paid down $200
million of its $1.0 billion term loan maturing in March 2023, decreasing
the remaining balance to $800 million.

Net debt to Adjusted EBITDA for the last quarter annualized was 5.2x,
after adjusting net debt to include the impact of proceeds from the
April 2019 settlement of shares of common stock sold through the ATM
equity program in March 2019, proceeds from the sale of GDS ADSs in
April 2019, and the repayment of $200 million of the $1.0 billion term
loan in April 2019. After further adjusting Adjusted EBITDA to exclude
the impact of the adoption of ASC 842 as of January 1, 2019, in order to
present the leverage metric on a basis comparable to that of prior
periods, net debt to Adjusted EBITDA for the last quarter annualized was
5.0x13. Available liquidity14 was $1.55 billion as
of March 31, 2019.

Dividend

On February 20, 2019, the Company announced a dividend of $0.46 per
share of common stock for the first quarter of 2019. The dividend was
paid on April 12, 2019, to stockholders of record at the close of
business on March 29, 2019.

Additionally, today the Company is announcing a dividend of $0.46 per
share of common stock for the second quarter of 2019. The dividend will
be paid on July 12, 2019, to stockholders of record at the close of
business on June 28, 2019.

Guidance

CyrusOne is updating guidance for full year 2019, increasing the
guidance range for Normalized FFO per diluted common share, decreasing
and tightening the guidance ranges for Capital Expenditures and Capital
Expenditures – Development, and reaffirming the ranges for all other
metrics. The annual guidance provided below represents forward-looking
statements, which are based on current economic conditions, internal
assumptions about the Company’s existing customer base, and the supply
and demand dynamics of the markets in which CyrusOne operates.

CyrusOne does not provide forward-looking guidance for GAAP financial
measures (other than Revenue and Capital Expenditures) or
reconciliations for the non-GAAP financial measures included in the
annual guidance provided below due to the inherent difficulty in
forecasting and quantifying certain amounts that are necessary for such
reconciliations, including net income (loss) and adjustments that could
be made for transaction, acquisition, integration and other related
expenses, legal claim costs, asset impairments and loss on disposals and
other charges in its reconciliation of historic numbers, the amount of
which, based on historical experience, could be significant.

Category

     

Previous
2019 Guidance

     

Revised
2019 Guidance

Total Revenue $960 – 1,000 million $960 – 1,000 million
Lease and Other Revenues from Customers $835 – 865 million $835 – 865 million
Metered Power Reimbursements $125 – 135 million $125 – 135 million
Adjusted EBITDA $500 – 525 million $500 – 525 million
Normalized FFO per diluted common share $3.10 – 3.20 $3.30 – 3.40
Capital Expenditures $950 – 1,100 million $900 – 1,000 million
Development(1) $940 – 1,085 million $890 – 985 million
Recurring $10 – 15 million $10 – 15 million
 

(1) Development capital expenditures include the
acquisition of land for future development.

Upcoming Conferences and Events

  • MoffettNathanson Media & Communications Summit on May 14-15 in New
    York City
  • J.P. Morgan Global Technology, Media and Communications Conference on
    May 13-16 in Boston, Massachusetts
  • RBC C-Level 2019 Global Datacenter and Connectivity Conference on May
    29 in the San Francisco Bay Area
  • Cowen Technology, Media & Telecom Conference on May 29-30 in New York
    City
  • Credit Suisse Communications Conference on June 4-5 in New York City
  • NAREIT’s REITweek Conference on June 4-6 in New York City
  • William Blair Growth Stock Conference on June 5-6 in Chicago
  • NASDAQ Investor Conference on June 13 in London

Conference Call Details

CyrusOne will host a conference call on May 2, 2019, at 11:00 AM Eastern
Time (10:00 AM Central Time) to discuss its results for the first
quarter of 2019. A live webcast of the conference call and the
presentation to be made during the call will be available in the
“Investors / Events & Presentations” section of the Company’s website at http://investor.cyrusone.com/events.cfm.
The U.S. conference call dial-in number is 1-844-492-3731, and the
international dial-in number is 1-412-542-4121. A replay will be
available one hour after the conclusion of the earnings call on May 2,
2019, through May 16, 2019. The U.S. toll-free replay dial-in number is
1-877-344-7529 and the international replay dial-in number is
1-412-317-0088. The replay access code is 10129894.

Safe Harbor

This release and the documents incorporated by reference herein contain
forward-looking statements regarding future events and our future
results that are subject to the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, are statements that could be deemed
forward-looking statements. These statements are based on current
expectations, estimates, forecasts, and projections about the industries
in which we operate and the beliefs and assumptions of our management.
Words such as “expects,” “anticipates,” “predicts,” “projects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “continues,”
“endeavors,” “strives,” “may,” variations of such words and similar
expressions are intended to identify such forward-looking statements. In
addition, any statements that refer to projections of our future
financial performance, our anticipated growth and trends in our
businesses, and other characterizations of future events or
circumstances are forward-looking statements. Readers are cautioned
these forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties, which could
cause our actual results to differ materially and adversely from those
reflected in the forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those
discussed in this release and those discussed in other documents we file
with the Securities and Exchange Commission (SEC). More information on
potential risks and uncertainties is available in our recent filings
with the SEC, including CyrusOne’s Form 10-K report, Form 10-Q reports,
and Form 8-K reports. We undertake no obligation to revise or update any
forward-looking statements for any reason other than as required by law.

Adoption of New Accounting Standard and Use of Non-GAAP Financial
Measures and Other Metrics

In February 2016, the Financial Accounting Standards Board issued ASU
2016-02 (codified in ASC 842, Leases (“ASC 842”)) to increase
transparency and comparability among organizations by recognizing lease
assets and lease liabilities on the balance sheet and disclosing key
information about leasing transactions. The ASU requires that a
liability be recorded on the balance sheet for all leases where the
reporting entity is a lessee, based on the present value of future lease
obligations. A corresponding right-of-use asset will also be recorded.
Amortization of the lease obligation and the right-of-use asset for
leases classified as operating leases are on a straight-line basis.
Leases classified as financing leases are required to be accounted for
as financing arrangements similar to the accounting treatment for
capital leases under ASC 840, Leases (the former accounting
standard for all leases).

We adopted ASU 2016-02 on January 1, 2019, applied the package of
practical expedients included therein and utilized the modified
retrospective transition method, with the cumulative effect of
transition, including initial recognition of lease assets and
liabilities for existing operating leases, recognized as of the
effective date, included in ASU 2018-11. By applying ASU 2018-11 at the
adoption date, the presentation of financial information for periods
prior to January 1, 2019 will remain unchanged.

This press release contains certain non-GAAP financial measures that
management believes are helpful in understanding the Company’s business,
as further discussed within this press release. These financial
measures, which include Funds From Operations, Normalized Funds From
Operations, Normalized Funds From Operations per Diluted Common Share,
Adjusted EBITDA, Net Operating Income, and Net Debt should not be
construed as being more important than comparable GAAP measures.
Detailed reconciliations of these non-GAAP financial measures to
comparable GAAP financial measures have been included in the tables that
accompany this release and are available in the Investor Relations
section of www.cyrusone.com.

Management uses FFO, Normalized FFO, Normalized FFO per Diluted Common
Share, Adjusted EBITDA, and NOI as supplemental performance measures
because they provide performance measures that, when compared year over
year, capture trends in occupancy rates, rental rates and operating
costs. The Company also believes that, as widely recognized measures of
the performance of real estate investment trusts (REITs) and other
companies, these measures will be used by investors as a basis to
compare its operating performance with that of other companies. Other
companies may not calculate these measures in the same manner, and, as
presented, they may not be comparable to others. Therefore, FFO,
Normalized FFO, NOI, and Adjusted EBITDA should be considered only as
supplements to net income as measures of our performance. FFO,
Normalized FFO, NOI, and Adjusted EBITDA should not be used as measures
of liquidity or as indicative of funds available to fund the Company’s
cash needs, including the ability to make distributions. These measures
also should not be used as substitutes for cash flow from operating
activities computed in accordance with U.S. GAAP. The Company believes
that Net Debt provides a useful measure of liquidity and financial
health.

1 The Company adopted ASC 842 effective January 1, 2019. The
adjusted 1Q’18 results have not been prepared in accordance with GAAP
and represent the Company’s estimates as if the standard had been
adopted as of January 1, 2018. The percentage changes versus adjusted
1Q’18 results are being shown solely for comparative and investor
usefulness purposes with respect to the Company’s 1Q’19 results. There
is no impact on 1Q’18 Revenue. The estimated impacts on 1Q’18 Net
income, Adjusted EBITDA, Normalized FFO, Net income per share, and
Normalized FFO per share are $1.2 million, $4.1 million, $2.2 million,
$0.01, and $0.02, respectively.

2CyrusOne is not providing forward-looking GAAP guidance for
GAAP net income (loss) per share or reconciliations of its non-GAAP
guidance, see “Guidance” for more information.

3Net income (loss) per diluted common share is defined as net
income (loss) divided by the weighted average diluted common shares
outstanding for the period, which were 108.8 million for the first
quarter of 2019.

4We use Net Operating Income (“NOI”), which is a non-GAAP
financial measure commonly used in the REIT industry, as a supplemental
performance measure. We use NOI as a supplemental performance measure
because, when compared period over period, it captures trends in
occupancy rates, rental rates and operating expenses. We also believe
that, as a widely recognized measure of the performance of REITs, NOI is
used by investors as a basis to evaluate REITs.

We calculate NOI as revenue less property operating expenses, each of
which are presented in the accompanying consolidated statements of
operations and/or net income (loss), which is presented in the
accompanying consolidated statements of operations, adjusted for sales
and marketing expenses, general and administrative expenses,
depreciation and amortization expenses, transaction, acquisition,
integration and other related expenses, interest expense, unrealized
(gain) loss on marketable equity investment, loss on early
extinguishment of debt, other expense, income tax expense and other
special items as appropriate. Amortization of deferred leasing costs is
presented in depreciation and amortization expenses, which is excluded
from NOI. Sales and marketing expenses are not property-specific, rather
these expenses support our entire portfolio. As a result, we have
excluded these sales and marketing expenses from our NOI calculation,
consistent with the treatment of general and administrative expenses,
which also support our entire portfolio. Because the calculation of NOI
excludes various expenses, the utility of NOI as a measure of our
performance is limited. Other REITs may not calculate NOI in the same
manner. Accordingly, our NOI may not be comparable to others. Therefore,
NOI should be considered only as a supplement to revenue and to net
income (loss) presented in accordance with GAAP as a measure of our
performance. NOI should not be used as a measure of our liquidity or as
indicative of funds available to fund our cash needs, including our
ability to make distributions. NOI also should not be used as a
supplement to or substitute for cash flow from operating activities
computed in accordance with GAAP.

5Adjusted EBITDA, which is a non-GAAP financial measure, is
defined as net income (loss) as defined by GAAP adjusted for interest
expense, income tax benefit (expense), depreciation and amortization,
impairment losses and loss on disposals, transaction, acquisition,
integration and other related expenses, legal claim costs, stock-based
compensation expense, severance and management transition costs, loss on
early extinguishment of debt, new accounting standards and regulatory
compliance and the related system implementation costs, unrealized
(gain) loss on marketable equity investment, other expenses and other
special items as appropriate. Other companies may not calculate Adjusted
EBITDA in the same manner. Accordingly, the Company’s Adjusted EBITDA as
presented may not be comparable to others.

6We use funds from operations (“FFO”) and normalized funds
from operations (“Normalized FFO”), which are non-GAAP financial
measures commonly used in the REIT industry, as supplemental performance
measures. We use FFO and Normalized FFO as supplemental performance
measures because, when compared period over period, they capture trends
in occupancy rates, rental rates and operating costs. We also believe
that, as widely recognized measures of the performance of REITs, FFO and
Normalized FFO are used by investors as a basis to evaluate REITs.

We calculate FFO as net income (loss) computed in accordance with GAAP
before real estate depreciation and amortization and impairment losses.
While it is consistent with the definition of FFO promulgated by the
National Association of Real Estate Investment Trusts (“NAREIT”), our
computation of FFO may differ from the methodology for calculating FFO
used by other REITs. Accordingly, our FFO may not be comparable to
others.

We calculate Normalized FFO as FFO plus loss on early extinguishment of
debt; unrealized (gain) loss on marketable equity investment; new
accounting standards and regulatory compliance and the related system
implementation costs; amortization of tradenames; transaction,
acquisition, integration and other related expenses; severance and
management transition costs; legal claim costs; lease exit costs; and
other special items as appropriate. The Company believes its Normalized
FFO calculation provides a comparable measure between different periods.
Other REITs may not calculate Normalized FFO in the same manner.
Accordingly, our Normalized FFO may not be comparable to others.

In addition, because FFO and Normalized FFO exclude real estate
depreciation and amortization and impairment losses, and capture neither
the changes in the value of our properties that result from use or from
market conditions, nor the level of capital expenditures and leasing
commissions necessary to maintain the operating performance of our
properties, all of which have real economic effect and could materially
impact our results from operations, the utility of FFO and Normalized
FFO as measures of our performance is limited. Therefore, FFO and
Normalized FFO should be considered only as supplements to net income
(loss) presented in accordance with GAAP as measures of our performance.
FFO and Normalized FFO should not be used as measures of our liquidity
or as indicative of funds available to fund our cash needs, including
our ability to make distributions.

Contacts

Investor Relations
Michael Schafer
Vice President,
Capital Markets & Investor Relations
972-350-0060
[email protected]

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading

Cannabis

Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania